CVKD — Cadrenal Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1937993 ·
Last close
$0.93
Market Cap
$3.32M
52W High
$14.50
52W Low
$0.85
ADV30
918,008
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,340,400 | -3,322,565 | 5,588,965 | 2,388,135 | 1,497,257 |
| Mar 2026 | 0 | — | -2,514,378 | -2,496,540 | 2,862,067 | 2,308,137 | 1,064,952 |
| Dec 2025 | 0 | — | -3,065,106 | -3,038,990 | 4,326,708 | 4,007,789 | 1,587,982 |
| Sep 2025 | 0 | — | -2,733,803 | -2,685,705 | 4,087,622 | 3,860,082 | 1,352,675 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,955,128
Investing CF
$-1,853
Financing CF
$5,929,046
CapEx
$-5,104
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.31
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-41,456,685
Inventory
—
Receivables
$5,466
ST Investments
—
EBIT TTM
$-12,047,578
Pretax Income TTM
$-11,888,522
Interest Exp TTM
$0
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,461,177 | -13,237,362 | 4,326,708 | 1,587,982 | 2,738,726 | -12,601,666 |
| Dec 2024 | 0 | -10,960,619 | -10,651,368 | 10,123,533 | 2,683,958 | 7,439,575 | -7,357,550 |
| Dec 2023 | 0 | -7,632,843 | -8,357,086 | 8,519,250 | 826,875 | 7,692,375 | -3,530,323 |
| Dec 2022 | — | — | — | 778,174 | 6,329,324 | -5,551,150 | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-11,888,522
OpCashFlow TTM
—
Assets (Latest)
$2,862,067
Forward EPS
$-3.40
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | $3.32M | $0.06 | — |
| XRTX | XORTX Therapeutics Inc. | $3.36M | $1.85 | — |
| APVO | Aptevo Therapeutics Inc. | $3.26M | $1.80 | — |
| KAPA | Kairos Pharma, LTD. | $3.25M | $0.96 | — |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $3.25M | $5.55 | — |
News headlines (Yahoo Finance, 1h cache)
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
2026-10-07 11:00 · Yahoo
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
2026-09-21 20:30 · Yahoo
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
2026-09-03 12:00 · Yahoo
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
2026-08-31 12:00 · Yahoo
CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
2026-08-31 11:03 · Yahoo
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
2026-08-13 20:15 · Yahoo
CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy
2026-08-03 16:15 · Yahoo
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
2026-07-21 12:00 · Yahoo
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
2026-07-13 13:00 · Yahoo
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-07-01 00:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.